These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

671 related articles for article (PubMed ID: 9738560)

  • 1. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.
    Ravaud A; Chevreau C; Cany L; Houyau P; Dohollou N; Roché H; Soubeyran P; Bonichon F; Mihura J; Eghbali H; Tabah I; Bui BN
    J Clin Oncol; 1998 Sep; 16(9):2930-6. PubMed ID: 9738560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.
    Mayordomo JI; Rivera F; Díaz-Puente MT; Lianes P; Colomer R; López-Brea M; López E; Paz-Ares L; Hitt R; García-Ribas I
    J Natl Cancer Inst; 1995 Jun; 87(11):803-8. PubMed ID: 7540696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia.
    Vellenga E; Uyl-de Groot CA; de Wit R; Keizer HJ; Löwenberg B; ten Haaft MA; de Witte TJ; Verhagen CA; Stoter GJ; Rutten FF; Mulder NH; Smid WM; de Vries EG
    J Clin Oncol; 1996 Feb; 14(2):619-27. PubMed ID: 8636779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
    Jones SE; Schottstaedt MW; Duncan LA; Kirby RL; Good RH; Mennel RG; George TK; Snyder DA; Watkins DL; Denham CA; Hoyes FA; Rubin AS
    J Clin Oncol; 1996 Nov; 14(11):2976-83. PubMed ID: 8918495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment costs and quality of life with granulocyte-macrophage colony-stimulating factor in patients with antineoplastic therapy-related febrile neutropenia. Results of a randomised placebo-controlled trial.
    Uyl-de Groot CA; Vellenga E; de Vries EG; Löwenberg B; Stoter GJ; Rutten FF
    Pharmacoeconomics; 1997 Sep; 12(3):351-60. PubMed ID: 10170460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prevention and treatment of febrile neutropenia].
    Montemurro F; Gallicchio M; Aglietta M
    Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group.
    Ozkaynak MF; Krailo M; Chen Z; Feusner J
    Pediatr Blood Cancer; 2005 Sep; 45(3):274-80. PubMed ID: 15806544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granulocyte-macrophage colony-stimulating factor in association with high-dose chemotherapy (VETOPEC) for childhood solid tumors: a report from the Australia and New Zealand Children's Cancer Study Group.
    McCowage GB; White L; Carpenter P; Lockwood L; Toogood I; Tiedemann K; Shaw PJ
    Med Pediatr Oncol; 1997 Aug; 29(2):108-14. PubMed ID: 9180912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin.
    Yau JC; Neidhart JA; Triozzi P; Verma S; Nemunaitis J; Quick DP; Mayernik DG; Oette DH; Haynes FA; Holcenberg J
    Am J Hematol; 1996 Apr; 51(4):289-95. PubMed ID: 8602629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial.
    García-Carbonero R; Mayordomo JI; Tornamira MV; López-Brea M; Rueda A; Guillem V; Arcediano A; Yubero A; Ribera F; Gómez C; Trés A; Pérez-Gracia JL; Lumbreras C; Hornedo J; Cortés-Funes H; Paz-Ares L
    J Natl Cancer Inst; 2001 Jan; 93(1):31-8. PubMed ID: 11136839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy.
    Marina NM; Shema SJ; Bowman LC; Rodman J; Douglass EC; Furman WL; Pappo A; Santana VM; Hudson M; Meyer WH
    Med Pediatr Oncol; 1994; 23(4):328-34. PubMed ID: 8058003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy.
    Wexler LH; Weaver-McClure L; Steinberg SM; Jacobson J; Jarosinski P; Avila N; Pizzo PA; Horowitz ME
    J Clin Oncol; 1996 Mar; 14(3):901-10. PubMed ID: 8622038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of granulocyte and granulocyte-macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study.
    Thomas X; Boiron JM; Huguet F; Reman O; Sutton L; Turlure P; Garban F; Gardin C; Espinouse D; Boulat O; Lhéritier V; Fiere D;
    Hematol J; 2004; 5(5):384-94. PubMed ID: 15448664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte-macrophage colony-stimulating factor in neutropenic children with malignancies.
    Lydaki E; Bolonaki E; Stiakaki E; Dimitriou H; Kalmantis T; Kalmanti M
    Pediatr Hematol Oncol; 1995; 12(6):551-8. PubMed ID: 8589000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
    Bruserud O; Foss B; Petersen H
    Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of febrile neutropenic patients on granulocyte colony stimulating factor in a tertiary care hospital.
    Osmani AH; Ansari TZ; Masood N; Ahmed B
    Asian Pac J Cancer Prev; 2012; 13(6):2523-6. PubMed ID: 22938399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
    Yang S; Shi YK; Liu P; Han XH; He XH; Cai YM; Chen ZM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):339-44. PubMed ID: 16900629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of benefit of granulocyte macrophage or granulocyte colony stimulating factor in patients with febrile neutropenia.
    Siddiqui T; Burney IA; Kakepoto GN; Khurshid M; Salam A; Smego RA
    J Pak Med Assoc; 2002 May; 52(5):206-10. PubMed ID: 12174492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
    Bunn PA; Crowley J; Kelly K; Hazuka MB; Beasley K; Upchurch C; Livingston R; Weiss GR; Hicks WJ; Gandara DR
    J Clin Oncol; 1995 Jul; 13(7):1632-41. PubMed ID: 7602352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.